Morgan Stanley Verrica Pharmaceuticals Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Morgan Stanley holds 69,423 shares of VRCA stock, worth $551,912. This represents 0.0% of its overall portfolio holdings.

Number of Shares

69,423

Previous 361,787 80.81%

Holding current value

$551,912

Previous $2.88 Million 80.84%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	N/A	-292,364 Reduced 80.81%	69,423 $551,000
Q4 2024 Feb 14, 2025	BUY	N/A	180,006 Added 99.02%	361,787 $2.88 Million
Q3 2024 May 14, 2025	BUY	$7.95 - $7.95 $769,893 - $769,893	96,842 Added 114.01%	181,781 $1.45 Million
Q3 2024 Nov 14, 2024	BUY	$7.95 - $7.95 $769,893 - $769,893	96,842 Added 114.01%	181,781 $1.45 Million
Q2 2024 May 14, 2025	SELL	$5.89 - $9.56 $1.63 Million - $2.65 Million	-276,848 Reduced 76.52%	84,939 $619,000
Q2 2024 Oct 17, 2024	SELL	$5.89 - $9.56 $290,241 - $471,088	-49,277 Reduced 36.71%	84,939 $619,000
Q2 2024 Aug 14, 2024	SELL	$5.89 - $9.56 $290,241 - $471,088	-49,277 Reduced 36.71%	84,939 $619,000
Q1 2024 Oct 17, 2024	BUY	$4.74 - $6.81 $233,572 - $335,576	49,277 Added 58.01%	134,216 $794,000
Q1 2024 Aug 16, 2024	BUY	$4.74 - $6.81 $108,598 - $156,023	22,911 Added 20.58%	134,216 $794,000
Q1 2024 May 15, 2024	BUY	$4.74 - $6.81 $108,598 - $156,023	22,911 Added 20.58%	134,216 $794,000
Q4 2023 Aug 16, 2024	BUY	$2.93 - $7.32 $77,252 - $192,999	26,366 Added 31.04%	111,305 $814,000
Q4 2023 Feb 13, 2024	SELL	$2.93 - $7.32 $22,490 - $56,188	-7,676 Reduced 6.45%	111,305 $814,000
Q3 2023 Nov 15, 2023	BUY	$3.75 - $7.46 $267,397 - $531,942	71,306 Added 149.57%	118,981 $461,000
Q2 2023 Aug 14, 2023	SELL	$5.32 - $6.79 $620,939 - $792,515	-116,718 Reduced 71.0%	47,675 $275,000
Q1 2023 May 15, 2023	BUY	$2.88 - $8.51 $435,271 - $1.29 Million	151,136 Added 1140.05%	164,393 $1.07 Million
Q4 2022 Feb 14, 2023	SELL	$2.09 - $3.39 $60,831 - $98,669	-29,106 Reduced 68.71%	13,257 $36,000
Q3 2022 Nov 14, 2022	SELL	$2.17 - $4.3 $112,245 - $222,421	-51,726 Reduced 54.98%	42,363 $123,000
Q2 2022 Oct 27, 2022	SELL	$1.81 - $8.93 $1.24 Million - $6.14 Million	-687,623 Reduced 87.96%	94,089 $181,000
Q2 2022 Aug 15, 2022	SELL	$1.81 - $8.93 $1.24 Million - $6.14 Million	-687,623 Reduced 87.96%	94,089 $181,000
Q1 2022 Oct 27, 2022	BUY	$7.59 - $9.49 $5.22 Million - $6.53 Million	687,623 Added 730.82%	781,712 $6.34 Million
Q1 2022 May 13, 2022	SELL	$7.59 - $9.49 $981,204 - $1.23 Million	-129,276 Reduced 14.19%	781,712 $6.34 Million
Q4 2021 Feb 14, 2022	BUY	$9.1 - $13.36 $7.88 Million - $11.6 Million	866,408 Added 1943.49%	910,988 $8.35 Million
Q3 2021 Nov 15, 2021	BUY	$9.55 - $13.96 $425,739 - $622,336	44,580 New	44,580 $556,000

Others Institutions Holding VRCA

# of Institutions

Shares Held

20.3M

Call Options Held

Put Options Held

View Full List

About Verrica Pharmaceuticals Inc.

Ticker VRCA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,094,100
Market Cap $327M
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...

More about VRCA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account